Metavia Stock Today
| MTVA Stock | 1.48 0.03 1.99% |
PerformanceVery Weak
| Odds Of DistressVery High
|
MetaVia is trading at 1.48 as of the 16th of March 2025, a 1.99% down since the beginning of the trading day. The stock's open price was 1.51. MetaVia has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. MetaVia symbol was changed from NRBO on 29th of November 2024. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
IPO Date | Category Healthcare |
MetaVia is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 8.62 M outstanding shares of which 49.12 K shares are now shorted by private and institutional investors with about 1.11 trading days to cover. More on MetaVia
Moving together with MetaVia Stock
Moving against MetaVia Stock
MetaVia Stock Highlights
| Older Symbol | NRBO |
| President CEO | HyungHeon Kim |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, NASDAQ Health Care, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation | |
MetaVia (MTVA) is traded on NASDAQ Exchange in USA. It is located in 545 Concord Avenue, Cambridge, MA, United States, 02138 and employs 8 people. MetaVia was previously known as NRBO Old and was traded on NASDAQ Exchange under the symbol NRBO. MetaVia is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.42 M. MetaVia conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 8.62 M outstanding shares of which 49.12 K shares are now shorted by private and institutional investors with about 1.11 trading days to cover.
MetaVia generates negative cash flow from operations
Check MetaVia Probability Of Bankruptcy
Ownership AllocationThe market capitalization of MetaVia is USD14.42 Million. MetaVia secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.46 % of MetaVia outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check MetaVia Ownership Details
MetaVia Historical Income Statement
MetaVia Stock Against Markets
MetaVia Corporate Management
| Marshall Woodworth | Chief Officer | Profile | |
| Christopher MD | Consulting Advisor | Profile | |
| Robert Homolka | Senior Operations | Profile | |
| MiKyung Kim | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MetaVia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade MetaVia Stock refer to our How to Trade MetaVia Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MetaVia. If investors know MetaVia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MetaVia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MetaVia is measured differently than its book value, which is the value of MetaVia that is recorded on the company's balance sheet. Investors also form their own opinion of MetaVia's value that differs from its market value or its book value, called intrinsic value, which is MetaVia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MetaVia's market value can be influenced by many factors that don't directly affect MetaVia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MetaVia's value and its price as these two are different measures arrived at by different means. Investors typically determine if MetaVia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MetaVia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.